

Janssen Pharmaceutical Companies of Johnson & Johnson

Selected Novel Therapies - Recent Approvals/Potential Filings*

(2021-2025 Key Filings, As Outlined at 2021 Pharm Business Review)

Selective Highlights as of July 19, 2022

Novel Therapies APPROVED

Oncology

RYBREVANT (amivantamab)
Non Small Cell Lung Cancer

CARVYKTI (Ciltacabtagene autoleucel)
Relapsed refractory Multiple Myeloma

Novel Therapies in REGISTRATION

Oncology

teclistamab (BCMA/CD3)
Relapsed refractory Multiple Myeloma

niraparib
^{EU} Metastatic castration-resistant prostate cancer (mCRPC)

Novel Therapies PLANNED FILINGS

Cardiovascular and Metabolism

RPGR AAV Gene Therapy
X-linked retinitis pigmentosa

aprocitentan
Difficult to treat hypertension

Milvexian (Factor XIa)
Prevention and Treatment of Thrombosis

Infectious Diseases and Vaccines

RSV Adult Vaccine
RSV vaccine

JNJ-3989 siRNA
HBV/HDV Co-infection

Immunology

Oral IL-23i
Psoriasis

Neuroscience

seltorexant
Adjunctive treatment for major depressive disorder with insomnia symptoms

Aticaprant
Adjunctive treatment for major depressive disorder

nipocalimab
Generalized Myasthenia Gravis

Oncology

TAR-200 (RIS/gemcitabine)
Bladder Cancer

talquetamab (GPCR5D/CD3)
Multiple myeloma

niraparib
^{US} Metastatic castration-resistant prostate cancer (mCRPC)

Pulmonary Hypertension

Macitentan 75mg
Pulmonary Arterial Hypertension



Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab); Lazertinib licensed from Yuhon Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx;